TrianglePeripheral Blood Stem Cell Transplant (NCT05805605)
Peripheral Blood Stem Cell Transplant trial for Acute Myelogenous Leukemia (NCT05805605). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for children and adults through age seventy-five with specified blood cancers or marrow-failure disorders eligible for donor transplantation. Disease-specific remission and prior-treatment requirements apply.
The idea: lower-intensity cyclophosphamide, fludarabine, and total-body radiation prepare patients for donor blood or marrow stem cells. Afterward, cyclophosphamide, sirolimus, and mycophenolate aim to prevent graft-versus-host disease. Researchers measure acute and chronic graft-versus-host disease over one year. Related, unrelated, or partly matched family donors may qualify.
This phase 2 study plans 56 patients. Mark Juckett leads at University of Minnesota, Minneapolis, the sole recruiting US site.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.